Other Clinical Trial - Personalized Neoantigen Vaccine in Combination With

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05509699` - Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer	Phase 2
Recruiting	`NCT05975944` - Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer	Phase 1/Phase 2
Not yet recruiting	`NCT04562337` - A Phase II Clinical Study of SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in Extensive Small Cell Lung Cancer	Phase 2
Completed	`NCT00616109` - Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC	Phase 2
Active, not recruiting	`NCT04373369` - Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer	Phase 2
Recruiting	`NCT04254471` - This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients	Phase 2/Phase 3
Active, not recruiting	`NCT04774380` - Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer	Phase 3
Active, not recruiting	`NCT01555710` - Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)	Phase 3
Completed	`NCT00682981` - A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 1/Phase 2
Recruiting	`NCT04702880` - A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer	Phase 2
Active, not recruiting	`NCT04487756` - Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer	Phase 1/Phase 2
Recruiting	`NCT03135977` - Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy	Phase 2
Completed	`NCT03913455` - Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer	Phase 2
Recruiting	`NCT04663438` - Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC
Not yet recruiting	`NCT03971214` - PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer	Phase 1
Active, not recruiting	`NCT04101357` - Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411	Phase 1/Phase 2
Not yet recruiting	`NCT04404543` - A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer	Phase 1
Completed	`NCT04636762` - A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)	Phase 2
Completed	`NCT02323737` - Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer	Phase 2
Completed	`NCT03911219` - Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy

NCT number	NCT04397003
Study type	Interventional
Source	Washington University School of Medicine
Contact	Jeffrey Ward, M.D., Ph.D.
Phone	314-747-7409
Email	jward2@wustl.edu
Status	Recruiting
Phase	Phase 2
Start date	March 30, 2022
Completion date	March 31, 2030

Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms